Skip to main content

Evaluation of Different Glycoforms of Honeybee Venom Major Allergen Phospholipase A2 (Api m 1) Produced in Insect Cells

Buy Article:

$55.00 plus tax (Refund Policy)

Allergic reactions to hymenoptera stings are one of the major reasons for IgE-mediated anaphylaxis. However, proper diagnosis using venom extracts is severely affected by molecular cross-reactivity. In this study recombinant honeybee venom major allergen phospholipase A2 (Api m 1) was produced for the first time in insect cells. Using baculovirus infection of different insect cell lines allergen versions providing a varying degree of cross-reactive carbohydrate determinants as well as a non glycosylated variant could be obtained as secreted soluble proteins in high yields. The resulting molecules were analyzed for their glycosylation and proved to show advantageous properties regarding cross-reactivity in sIgE-based assays. Additionally, in contrast to the enzymatically active native protein the inactivated allergen did not induce IgE-independent effector cell activation. Thus, insect cell-derived recombinant Api m 1 with defined CCD phenotypes might provide further insights into hymenoptera venom IgE reactivities and contribute to an improved diagnosis of hymenoptera venom allergy.

No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Allergen; Allergen Phospholipase A2; CCD phenotypes; Glycoforms; HBV acid phosphatase; Honeybee Venom; IgE-mediated anaphylaxis; MUXF-HAS; RBL-SX38; Recombinant Baculovirus; Site Directed Mutagenesis; agglutinin; baculovirus; carbohydrates; cross-reactivity; honeybee; hymenoptera stings; hymenoptera venom; phospholipase; recombinant allergen; venom allergy

Document Type: Research Article

Publication date: 2011-04-01

More about this publication?
  • Protein & Peptide Letters publishes short papers in all important aspects of protein and peptide research, including structural studies, recombinant expression, function, synthesis, enzymology, immunology, molecular modeling, drug design etc. Manuscripts must have a significant element of novelty, timeliness and urgency that merit rapid publication. Reports of crystallisation, and preliminary structure determinations of biologically important proteins are acceptable. Purely theoretical papers are also acceptable provided they provide new insight into the principles of protein/peptide structure and function.
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more